Clinical Partnerships Arima's January 2026 Fox Chase Cancer Center collaboration to deploy 3D genome diagnostics into routine clinical practice, along with the 2025 BioTech Breakthrough award, validates the solution and creates a credible path for hospital systems to adopt Hi-C based workflows for cancer diagnostics; target major cancer centers for co-developed validation studies and integrated reporting.

Europe Growth The upcoming AMP Europe event on June 15, 2026 and prior international interest signal a frontline opportunity to expand sales in Europe by partnering with labs, CROs, and academic centers, offering localized support and cloud-enabled collaboration.

Growth Capital A 22M Series C in 2025 and mid-range revenue indicate capacity to scale; pursue strategic partnerships and licensing of Arima's 3D genomics informatics tools, with ecosystem integrations (for example with Velsera/Pierian workflows) to accelerate lab adoption.

Leadership Momentum New CEO Tom Willis appointed in 2025 suggests a strategic growth plan; engage executives on enterprise sales cycles, pilots, and long-term partnerships to drive large-scale deployments in oncology and clinical diagnostics.

3D Genomics Edge Differentiated value from Hi-C sequencing outperforming high-coverage WGS for lymphoma detection and an award-winning clinical diagnostics solution positions Arima as a preferred partner for oncology labs and pharma, enabling upsell into cancer diagnostics, gene fusion detection, and precision medicine via hosted cloud analyses.